Overview
- A JAMA Internal Medicine secondary analysis of the SOUL trial found a 22% reduction in hospitalizations and deaths from heart failure among participants with type 2 diabetes who had heart failure at baseline.
- The benefit was greatest in HFpEF, with a 41% lower risk of heart failure–related events, while no statistically significant benefit was seen in HFrEF.
- No heart-failure benefit was detected in participants without heart failure at the start of the study.
- The randomized, double-blind trial enrolled about 9,650 people across 33 countries and followed them for nearly four years on daily oral semaglutide versus placebo.
- Serious adverse events occurred at similar rates in both groups, though investigators noted the analysis was exploratory, the trial was funded by Novo Nordisk, and longer-term safety warrants continued monitoring.